[
    [
        {
            "time": "",
            "original_text": "健康元营收增速放缓 引入战投高瓴资本获两涨停 盈利能力下降",
            "features": {
                "keywords": [
                    "健康元",
                    "营收增速",
                    "高瓴资本",
                    "涨停",
                    "盈利能力"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健康元营收增速放缓 引入战投高瓴资本获两涨停 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "高瓴定增凯莱英：战略投资者和上市公司是如何在定增中双赢的？",
            "features": {
                "keywords": [
                    "高瓴",
                    "定增",
                    "凯莱英",
                    "战略投资者",
                    "双赢"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴定增凯莱英：战略投资者和上市公司是如何在定增中双赢的？",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本A股布局青睐医药股 全额认购健康元定增",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "A股",
                    "医药股",
                    "健康元",
                    "定增"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本A股布局青睐医药股 全额认购健康元定增",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "高瓴资本全额认购健康元22亿募资 耗资70亿参与五公司定增浮盈44亿",
            "features": {
                "keywords": [
                    "高瓴资本",
                    "健康元",
                    "定增",
                    "募资",
                    "浮盈"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴资本全额认购健康元22亿募资 耗资70亿参与五公司定增浮盈44亿",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "original_text": "又来！高瓴22亿抢食GSK、AZ，百亿定增迎来降温打击？",
            "features": {
                "keywords": [
                    "高瓴",
                    "GSK",
                    "AZ",
                    "定增",
                    "降温",
                    "打击"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "又来！高瓴22亿抢食GSK、AZ，百亿定增迎来降温打击？",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]